Protara Therapeutics, Inc.
TARA
$6.19
$0.284.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -52.90M | -50.86M | -45.42M | -44.60M | -42.05M |
| Total Depreciation and Amortization | 351.00K | 347.00K | 332.00K | 332.00K | 357.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.54M | 3.47M | 3.98M | 4.45M | 5.21M |
| Change in Net Operating Assets | 285.00K | 2.34M | 966.00K | 4.01M | 1.29M |
| Cash from Operations | -48.72M | -44.71M | -40.14M | -35.81M | -35.20M |
| Capital Expenditure | -70.00K | -74.00K | -107.00K | -63.00K | -63.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -90.01M | -112.89M | -62.19M | 19.22M | 11.24M |
| Cash from Investing | -90.08M | -112.97M | -62.30M | 19.16M | 11.17M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 106.45M | 151.44M | 151.56M | 149.03M | 45.13M |
| Repurchase of Common Stock | -185.00K | -185.00K | -192.00K | -83.00K | -83.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.67M | -51.66M | -9.70M | -9.09M | -3.03M |
| Cash from Financing | 99.60M | 99.59M | 141.67M | 139.87M | 42.02M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -39.21M | -58.09M | 39.23M | 123.21M | 17.99M |